{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:06:14Z","timestamp":1760385974121},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have particular, immune-related adverse events (irAEs), as a consequence of interfering with self-tolerance mechanisms. The incidence of irAEs varies depending on ICI class, administered dose and treatment schedule. The aim of this study was to define a baseline (T0) immune profile (IP) predictive of irAE development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective, multicenter study evaluating the immune profile (IP) of 79 patients with advanced cancer and treated with anti-programmed cell death protein 1 (anti-PD-1) drugs as a first- or second-line setting was performed. The results were then correlated with irAEs onset. The IP was studied by means of multiplex assay, evaluating circulating concentration of 12 cytokines, 5 chemokines, 13 soluble immune checkpoints and 3 adhesion molecules. Indoleamine 2, 3-dioxygenase (IDO) activity was measured through a modified liquid chromatography\u2013tandem mass spectrometry using the high-performance liquid chromatography-mass spectrometry (HPLC\u2013MS\/MS) method. A connectivity heatmap was obtained by calculating Spearman correlation coefficients. Two different networks of connectivity were constructed, based on the toxicity profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Toxicity was predominantly of low\/moderate grade. High-grade irAEs were relatively rare, while cumulative toxicity was high (35%). Positive and statistically significant correlations between the cumulative toxicity and IP10 and IL8, sLAG3, sPD-L2, sHVEM, sCD137, sCD27 and sICAM-1 serum concentration were found. Moreover, patients who experienced irAEs had a markedly different connectivity pattern, characterized by disruption of most of the paired connections between cytokines, chemokines and connections of sCD137, sCD27 and sCD28, while sPDL-2 pair-wise connectivity values seemed to be intensified. Network connectivity analysis identified a total of 187 statistically significant interactions in patients without toxicity and a total of 126 statistically significant interactions in patients with toxicity. Ninety-eight interactions were common to both networks, while 29 were specifically observed in patients who experienced toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A particular, common pattern of immune dysregulation was defined in patients developing irAEs. This immune serological profile, if confirmed in a larger patient population, could lead to the design of a personalized therapeutic strategy in order to prevent, monitor and treat irAEs at an early stage.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00262-023-03384-9","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T17:02:43Z","timestamp":1677862963000},"page":"2217-2231","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach"],"prefix":"10.1007","volume":"72","author":[{"given":"Andrea","family":"Botticelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pomati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Schinzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silverio","family":"Tomao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Fiscon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Scagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pisegna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciurluini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Chiavassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasan","family":"Amirhassankhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvia","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria Grazia","family":"Zizzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Napoletano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelia","family":"Rughetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Nuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"19","key":"3384_CR1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"10375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 10375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"10027","key":"3384_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL Jr, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"6","key":"3384_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, Carter BW, Patel SP (2021) Nivolumab and Ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol 39(6):599\u2013607. https:\/\/doi.org\/10.1200\/JCO.20.00605","journal-title":"J Clin Oncol"},{"issue":"8","key":"3384_CR4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2174\/0929867326666190704141444","volume":"27","author":"S Ka\u0161telan","year":"2020","unstructured":"Ka\u0161telan S, Antunica AG, Oreskovi\u0107 LB, Pel\u010di\u0107 G, Kasun E, Hat K (2020) Immunotherapy for uveal melanoma-current knowledge and perspectives. Curr Med Chem 27(8):1350\u20131366. https:\/\/doi.org\/10.2174\/0929867326666190704141444","journal-title":"Curr Med Chem"},{"issue":"5","key":"3384_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2021.1898587","volume":"30","author":"C Masaoutis","year":"2021","unstructured":"Masaoutis C, Kokkali S, Theocharis S (2021) Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Expert Opin Investig Drugs 30(5):555\u2013569. https:\/\/doi.org\/10.1080\/13543784.2021.1898587","journal-title":"Expert Opin Investig Drugs"},{"issue":"19","key":"3384_CR6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10212","key":"3384_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr, Psyrri A, Bast\u00e9 N, Neupane P, Bratland \u00c5, Fuereder T, Hughes BGM, Mes\u00eda R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonz\u00e1lez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"8","key":"3384_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T (2021) KEYNOTE-564 investigators. adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385(8):683\u2013694. https:\/\/doi.org\/10.1056\/NEJMoa2106391","journal-title":"N Engl J Med"},{"issue":"12","key":"3384_CR9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21(12):1563\u20131573. https:\/\/doi.org\/10.1016\/S1470-2045(20)30436-8","journal-title":"Lancet Oncol"},{"issue":"9","key":"3384_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/bcp.14316","volume":"86","author":"Y Abdou","year":"2020","unstructured":"Abdou Y, Pandey M, Sarma M, Shah S, Baron J, Ernstoff MS (2020) Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol 86(9):1690\u20131702. https:\/\/doi.org\/10.1111\/bcp.14316","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3384_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T (2022) Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 19(1):37\u201350. https:\/\/doi.org\/10.1038\/s41571-021-00552-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3384_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando M, Ito M, Srirat T, Kondo T, Yoshimura A (2020) Memory T cell, exhaustion, and tumor immunity. Immunol Med 43(1):1\u20139. https:\/\/doi.org\/10.1080\/25785826.2019.1698261","journal-title":"Immunol Med"},{"issue":"1","key":"3384_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/med.21727","volume":"41","author":"MA Hossain","year":"2021","unstructured":"Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, Birnbaumer L, Yang Y (2021) Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev 41(1):156\u2013201. https:\/\/doi.org\/10.1002\/med.21727","journal-title":"Med Res Rev"},{"key":"3384_CR14","doi-asserted-by":"publisher","first-page":"669474","DOI":"10.3389\/fimmu.2021.669474","volume":"12","author":"A Basu","year":"2021","unstructured":"Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K (2021) Differentiation and regulation of TH Cells: a balancing act for cancer immunotherapy. Front Immunol 12:669474. https:\/\/doi.org\/10.3389\/fimmu.2021.669474","journal-title":"Front Immunol"},{"issue":"4","key":"3384_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22(4):39. https:\/\/doi.org\/10.1007\/s11912-020-0897-9","journal-title":"Curr Oncol Rep"},{"key":"3384_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00259-5","author":"RJ Sullivan","year":"2021","unstructured":"Sullivan RJ, Weber JS (2021) Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/s41573-021-00259-5","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3384_CR17","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4110\/in.2020.20","volume":"20","author":"J Choi","year":"2020","unstructured":"Choi J, Lee SY (2020) Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw 20(1):e9. https:\/\/doi.org\/10.4110\/in.2020.20","journal-title":"Immune Netw"},{"key":"3384_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/bs.apha.2021.01.002","volume":"91","author":"JB Jacob","year":"2021","unstructured":"Jacob JB, Jacob MK, Parajuli P (2021) Review of immune checkpoint inhibitors in immuno-oncology. Adv Pharmacol 91:111\u2013139. https:\/\/doi.org\/10.1016\/bs.apha.2021.01.002","journal-title":"Adv Pharmacol"},{"issue":"9","key":"3384_CR19","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/cncr.33457","volume":"127","author":"PJ Voon","year":"2021","unstructured":"Voon PJ, Cella D, Hansen AR (2021) Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer 127(9):1360\u20131368. https:\/\/doi.org\/10.1002\/cncr.33457","journal-title":"Cancer"},{"issue":"12","key":"3384_CR20","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"3","key":"3384_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly LE, Power DG, O\u2019Reilly \u00c1, Donnellan P, Cushen SJ, O\u2019Sullivan K, Twomey M, Woodlock DP, Redmond HP, Ryan AM (2017) The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer 116(3):310\u2013317. https:\/\/doi.org\/10.1038\/bjc.2016.431","journal-title":"Br J Cancer"},{"issue":"12","key":"3384_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1080\/0284186X.2021.1978540","volume":"60","author":"L Haik","year":"2021","unstructured":"Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E, Ravaud A, Domblides C, Daste A (2021) The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol 60(12):1597\u20131603. https:\/\/doi.org\/10.1080\/0284186X.2021.1978540","journal-title":"Acta Oncol"},{"issue":"5","key":"3384_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/aje\/kwv292","volume":"183","author":"NR Rose","year":"2016","unstructured":"Rose NR (2016) Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol 183(5):403\u2013406. https:\/\/doi.org\/10.1093\/aje\/kwv292","journal-title":"Am J Epidemiol"},{"issue":"2","key":"3384_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/acr.24115","volume":"73","author":"VL Kronzer","year":"2021","unstructured":"Kronzer VL, Crowson CS, Sparks JA, Myasoedova E, Davis J 3rd (2021) Family history of rheumatic, autoimmune, and nonautoimmune diseases and risk of rheumatoid arthritis. Arthritis Care Res 73(2):180\u2013187. https:\/\/doi.org\/10.1002\/acr.24115","journal-title":"Arthritis Care Res"},{"issue":"1","key":"3384_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","volume":"7","author":"NJ Shah","year":"2019","unstructured":"Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C (2019) Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer 7(1):353. https:\/\/doi.org\/10.1186\/s40425-019-0771-1","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3384_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijms22010042","volume":"22","author":"L Belluomini","year":"2020","unstructured":"Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D, Sposito M, Tregnago D, Casali M, Riva ST, Sartori G, Menis J, Milella M, Pilotto S (2020) Infections and Immunotherapy in lung cancer: a bad relationship? Int J Mol Sci 22(1):42. https:\/\/doi.org\/10.3390\/ijms22010042","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3384_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12967-021-02784-8","volume":"19","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Cirillo A, Pomati G, Cerbelli B, Scagnoli S, Roberto M, Gelibter A, Mammone G, Calandrella ML, Cerbelli E, Di Pietro FR, De Galitiis F, Lanzetta G, Cortesi E, Mezi S, Marchetti P (2021) The role of opioids in cancer response to immunotherapy. J Transl Med 19(1):119. https:\/\/doi.org\/10.1186\/s12967-021-02784-8","journal-title":"J Transl Med"},{"key":"3384_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","volume":"142","author":"S Buti","year":"2021","unstructured":"Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V et al (2021) Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer 142:18\u201328. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.033","journal-title":"Eur J Cancer"},{"issue":"7","key":"3384_CR29","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1097\/HJH.0000000000002799","volume":"39","author":"G Kichenadasse","year":"2021","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Sorich MJ, Hopkins AM (2021) Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes. J Hypertens 39(7):1274\u20131281. https:\/\/doi.org\/10.1097\/HJH.0000000000002799","journal-title":"J Hypertens"},{"issue":"6","key":"3384_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT, Danoff S (2018) Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest 154(6):1416\u20131423. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048","journal-title":"Chest"},{"issue":"2","key":"3384_CR31","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, P\u00e9rol M, Campana M, Gautschi O, Fr\u00fch M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Pr\u00e9vot G, Milia J, Mazieres J (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50(2):1700050. https:\/\/doi.org\/10.1183\/13993003.00050-2017","journal-title":"Eur Respir J"},{"issue":"4","key":"3384_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","volume":"42","author":"JH Kang","year":"2021","unstructured":"Kang JH, Bluestone JA, Young A (2021) Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines. Trends Immunol 42(4):293\u2013311. https:\/\/doi.org\/10.1016\/j.it.2021.02.006","journal-title":"Trends Immunol"},{"key":"3384_CR33","doi-asserted-by":"publisher","first-page":"670391","DOI":"10.3389\/fimmu.2021.670391","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M, Zhai X, Li J, Guan J, Xu S, Li Y, Zhu H (2021) The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front Immunol 12:670391. https:\/\/doi.org\/10.3389\/fimmu.2021.670391","journal-title":"Front Immunol"},{"key":"3384_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR (2022) Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-021-00588-9","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3384_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","volume":"11","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W (2021) Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B 11(4):941\u2013960. https:\/\/doi.org\/10.1016\/j.apsb.2020.12.018","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"3384_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","volume":"6","author":"V Mollica Poeta","year":"2019","unstructured":"Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019) Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol 6(10):379. https:\/\/doi.org\/10.3389\/fimmu.2019.00379","journal-title":"Front Immunol"},{"issue":"4","key":"3384_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","volume":"17","author":"AY Chen","year":"2021","unstructured":"Chen AY, Wolchok JD, Bass AR (2021) TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 17(4):213\u2013223. https:\/\/doi.org\/10.1038\/s41584-021-00584-4","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"3384_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/1759-7714.13341","volume":"11","author":"W Ke","year":"2020","unstructured":"Ke W, Zhang Li, Dai Y (2020) The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer 11(4):835\u2013839. https:\/\/doi.org\/10.1111\/1759-7714.13341","journal-title":"Thorac Cancer"},{"key":"3384_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G, Bulotta A, Signorelli D, Palmisano A, Vignale D, Peretto G, Sala S, Esposito A, Garassino M, Gregorc V, Dagna L (2021) Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med 93:87\u201394. https:\/\/doi.org\/10.1016\/j.ejim.2021.07.016","journal-title":"Eur J Intern Med"},{"key":"3384_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00933-z","author":"H Azadeh","year":"2022","unstructured":"Azadeh H, Alizadeh-Navaei R, Rezaiemanesh A, Rajabinejad M (2022) Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-022-00933-z","journal-title":"Inflammopharmacology"},{"issue":"1","key":"3384_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-018-2258-1","volume":"68","author":"MP Pistillo","year":"2019","unstructured":"Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P (2019) Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunol Immunother 68(1):97\u2013107. https:\/\/doi.org\/10.1007\/s00262-018-2258-1","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3384_CR42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/jpm10040208","volume":"10","author":"IG Zizzari","year":"2020","unstructured":"Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, Scagnoli S, Vernocchi P, Del Chierico F, Putignani L, Rughetti A, Marchetti P, Nuti M, Botticelli A, Napoletano C (2020) Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients. J Pers Med 10(4):208. https:\/\/doi.org\/10.3390\/jpm10040208","journal-title":"J Pers Med"},{"issue":"9","key":"3384_CR43","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.3390\/cancers12092620","volume":"12","author":"IG Zizzari","year":"2020","unstructured":"Zizzari IG, Napoletano C, Di Filippo A, Botticelli A, Gelibter A, Calabr\u00f2 F, Rossi E, Schinzari G, Urbano F, Pomati G, Scagnoli S, Rughetti A, Caponnetto S, Marchetti P, Nuti M (2020) Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma. Cancers 12(9):2620. https:\/\/doi.org\/10.3390\/cancers12092620","journal-title":"Cancers"},{"key":"3384_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2022.2034377","volume":"8","author":"E Rossi","year":"2022","unstructured":"Rossi E, Zizzari IG, Di Filippo A, Acampora A, Pagliara MM, Sammarco MG, Simmaco M, Lionetto L, Botticelli A, Bria E, Marchetti P, Blasi MA, Tortora G, Schinzari G, Nuti M (2022) Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. Hum Vaccin Immunother 8:1\u201310. https:\/\/doi.org\/10.1080\/21645515.2022.2034377","journal-title":"Hum Vaccin Immunother"},{"issue":"36","key":"3384_CR45","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"2","key":"3384_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","volume":"4","author":"J Dine","year":"2017","unstructured":"Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M (2017) Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs 4(2):127\u2013135. https:\/\/doi.org\/10.4103\/apjon.apjon_4_17","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"1","key":"3384_CR47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57(1):289\u2013300","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"1","key":"3384_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"AL Barab\u00e1si","year":"2011","unstructured":"Barab\u00e1si AL, Gulbahce N, Loscalzo J (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12(1):56\u201368. https:\/\/doi.org\/10.1038\/nrg2918","journal-title":"Nat Rev Genet"},{"issue":"1","key":"3384_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41540-020-00168-0","volume":"7","author":"P Paci","year":"2021","unstructured":"Paci P, Fiscon G, Conte F, Wang RS, Farina L, Loscalzo J (2021) Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. NPJ Syst Biol Appl 7(1):3. https:\/\/doi.org\/10.1038\/s41540-020-00168-0","journal-title":"NPJ Syst Biol Appl"},{"issue":"6","key":"3384_CR50","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1002\/wsbm.1489","volume":"12","author":"EK Silverman","year":"2020","unstructured":"Silverman EK, Schmidt HHHW, Anastasiadou E, Altucci L, Angelini M, Badimon L, Balligand JL, Benincasa G, Capasso G, Conte F, Di Costanzo A, Farina L, Fiscon G, Gatto L, Gentili M, Loscalzo J, Marchese C, Napoli C, Paci P, Petti M, Quackenbush J, Tieri P, Viggiano D, Vilahur G, Glass K, Baumbach J (2020) Molecular networks in network medicine: development and applications. Wiley Interdiscip Rev Syst Biol Med 12(6):e1489. https:\/\/doi.org\/10.1002\/wsbm.1489","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"21","key":"3384_CR51","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309\u20135337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020","journal-title":"Cell"},{"issue":"1","key":"3384_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"3384_CR53","doi-asserted-by":"publisher","first-page":"705096","DOI":"10.3389\/fimmu.2021.705096","volume":"12","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Cirillo A, Strigari L, Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Rocca CD, D\u2019Amati G, Polimeni A, Nuti M, Merlano MC, Mezi S, Marchetti P (2021) Anti-PD-1 and anti-PD-L1 in head and neck cancer: a network meta-analysis. Front Immunol 12:705096. https:\/\/doi.org\/10.3389\/fimmu.2021.705096","journal-title":"Front Immunol"},{"issue":"1","key":"3384_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6(1):56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"issue":"3","key":"3384_CR55","doi-asserted-by":"publisher","first-page":"E488","DOI":"10.1073\/pnas.1714765115","volume":"115","author":"B Piasecka","year":"2018","unstructured":"Piasecka B, Duffy D, Urrutia A, Quach H, Patin E, Posseme C, Bergstedt J, Charbit B, Rouilly V, MacPherson CR, Hasan M, Albaud B, Gentien D, Fellay J, Albert ML, Quintana-Murci L (2018) Milieu Int\u00e9rieur consortium. distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proc Natl Acad Sci U S A 115(3):E488\u2013E497. https:\/\/doi.org\/10.1073\/pnas.1714765115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3384_CR56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41590-018-0049-7","volume":"19","author":"E Patin","year":"2018","unstructured":"Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P, Hammer C, J\u00f6nsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M, Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M, Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML (2018) Milieu Int\u00e9rieur consortium natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat Immunol 19(3):302\u2013314. https:\/\/doi.org\/10.1038\/s41590-018-0049-7","journal-title":"Nat Immunol"},{"issue":"1","key":"3384_CR57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0014-5793(92)80909-z","volume":"307","author":"M Baggiolini","year":"1992","unstructured":"Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307(1):97\u2013101. https:\/\/doi.org\/10.1016\/0014-5793(92)80909-z","journal-title":"FEBS Lett"},{"issue":"12","key":"3384_CR58","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/thorax.55.12.1023","volume":"55","author":"J Hull","year":"2000","unstructured":"Hull J, Thomson A, Kwiatkowski D (2000) Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55(12):1023\u20131027. https:\/\/doi.org\/10.1136\/thorax.55.12.1023","journal-title":"Thorax"},{"issue":"5 Suppl","key":"3384_CR59","first-page":"456","volume":"64","author":"M Bickel","year":"1993","unstructured":"Bickel M (1993) The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol 64(5 Suppl):456\u2013460","journal-title":"J Periodontol"},{"issue":"5","key":"3384_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm 2005(5):273\u2013279. https:\/\/doi.org\/10.1155\/MI.2005.273","journal-title":"Mediat Inflamm"},{"issue":"12","key":"3384_CR61","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1001\/archneur.58.12.1975","volume":"58","author":"C Trebst","year":"2001","unstructured":"Trebst C, Ransohoff RM (2001) Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 58(12):1975\u20131980. https:\/\/doi.org\/10.1001\/archneur.58.12.1975","journal-title":"Arch Neurol"},{"issue":"5","key":"3384_CR62","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/08916930410001713124","volume":"37","author":"U Christen","year":"2004","unstructured":"Christen U, Von Herrath MG (2004) IP-10 and type 1 diabetes: a question of time and location. Autoimmunity 37(5):273\u2013282","journal-title":"Autoimmunity"},{"issue":"1","key":"3384_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0002-9440(10)64171-5","volume":"161","author":"P Romagnani","year":"2002","unstructured":"Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M (2002) Expression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves\u2019 disease. Am J Pathol 161(1):195\u2013206. https:\/\/doi.org\/10.1016\/S0002-9440(10)64171-5","journal-title":"Am J Pathol"},{"issue":"10","key":"3384_CR64","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/bjs.5401","volume":"93","author":"A Antonelli","year":"2006","unstructured":"Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P (2006) Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves\u2019 disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93(10):1226\u20131231. https:\/\/doi.org\/10.1002\/bjs.5401","journal-title":"Br J Surg"},{"issue":"11","key":"3384_CR65","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1210\/jc.2004-0977","volume":"89","author":"A Antonelli","year":"2004","unstructured":"Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M (2004) High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89(11):5496\u20135499. https:\/\/doi.org\/10.1210\/jc.2004-0977","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3384_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1530\/eje.1.01847","volume":"152","author":"A Antonelli","year":"2005","unstructured":"Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M (2005) Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152(2):171\u2013177. https:\/\/doi.org\/10.1530\/eje.1.01847","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3384_CR67","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4049\/jimmunol.159.3.1437","volume":"159","author":"MP Keane","year":"1997","unstructured":"Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM (1997) The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159(3):1437\u20131443","journal-title":"J Immunol"},{"issue":"10","key":"3384_CR68","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.4049\/jimmunol.163.10.5686","volume":"163","author":"MP Keane","year":"1999","unstructured":"Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM (1999) IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163(10):5686\u20135692","journal-title":"J Immunol"},{"issue":"6 Suppl","key":"3384_CR69","doi-asserted-by":"publisher","first-page":"298S","DOI":"10.1378\/chest.122.6_suppl.298s","volume":"122","author":"RM Strieter","year":"2002","unstructured":"Strieter RM, Belperio JA, Keane MP (2002) CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest 122(6 Suppl):298S-301S. https:\/\/doi.org\/10.1378\/chest.122.6_suppl.298s","journal-title":"Chest"},{"issue":"9","key":"3384_CR70","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1161\/01.ATV.0000235691.84430.86","volume":"26","author":"C Herder","year":"2006","unstructured":"Herder C, Baumert J, Thorand B, Martin S, L\u00f6wel H, Kolb H, Koenig W (2006) Chemokines and incident coronary heart disease: results from the MONICA\/KORA Augsburg case-cohort study, 1984\u20132002. Arterioscler Thromb Vasc Biol 26(9):2147\u20132152. https:\/\/doi.org\/10.1161\/01.ATV.0000235691.84430.86","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3384_CR71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/01.ATV.0000191633.52585","volume":"26","author":"D Rothenbacher","year":"2006","unstructured":"Rothenbacher D, M\u00fcller-Scholze S, Herder C, Koenig W, Kolb H (2006) Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 26(1):194\u2013199. https:\/\/doi.org\/10.1161\/01.ATV.0000191633.52585","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"3384_CR72","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1084\/jem.182.1.219","volume":"182","author":"AD Luster","year":"1995","unstructured":"Luster AD, Greenberg SM, Leder P (1995) The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 182(1):219\u2013231. https:\/\/doi.org\/10.1084\/jem.182.1.219","journal-title":"J Exp Med"},{"issue":"2","key":"3384_CR73","first-page":"91","volume":"15","author":"AM Witkowska","year":"2004","unstructured":"Witkowska AM, Borawska MH (2004) Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 15(2):91\u201398","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"3384_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/s1734-1140(09)70004-0","volume":"61","author":"C Lawson","year":"2009","unstructured":"Lawson C, Wolf S (2009) ICAM-1 signaling in endothelial cells. Pharmacol Rep 61(1):22\u201332. https:\/\/doi.org\/10.1016\/s1734-1140(09)70004-0","journal-title":"Pharmacol Rep"},{"issue":"10","key":"3384_CR75","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.3389\/fimmu.2019.03056","volume":"14","author":"N Haghayegh Jahromi","year":"2020","unstructured":"Haghayegh Jahromi N, Marchetti L, Moalli F, Duc D, Basso C, Tardent H, Kaba E, Deutsch U, Pot C, Sallusto F, Stein JV, Engelhardt B (2020) Intercellular Adhesion molecule-1 (ICAM-1) and ICAM-2 differentially contribute to peripheral activation and CNS entry of autoaggressive Th1 and Th17 cells in experimental autoimmune encephalomyelitis. Front Immunol 14(10):3056. https:\/\/doi.org\/10.3389\/fimmu.2019.03056","journal-title":"Front Immunol"},{"issue":"10","key":"3384_CR76","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1136\/jcp.45.10.880","volume":"45","author":"J Chow","year":"1992","unstructured":"Chow J, Hartley RB, Jagger C, Dilly SA (1992) ICAM-1 expression in renal disease. J Clin Pathol 45(10):880\u2013884. https:\/\/doi.org\/10.1136\/jcp.45.10.880","journal-title":"J Clin Pathol"},{"issue":"10","key":"3384_CR77","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.numecd.2010.02.023","volume":"21","author":"C Jublanc","year":"2011","unstructured":"Jublanc C, Beaudeux JL, Aubart F, Raphael M, Chadarevian R, Chapman MJ, Bonnefont-Rousselot D, Bruckert E (2011) Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: relevance to vascular inflammation. Nutr Metab Cardiovasc Dis 21(10):817\u2013822. https:\/\/doi.org\/10.1016\/j.numecd.2010.02.023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"3384_CR78","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/jpm11070651","volume":"11","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Zizzari IG, Scagnoli S, Pomati G, Strigari L, Cirillo A, Cerbelli B, Di Filippo A, Napoletano C, Scirocchi F, Rughetti A, Nuti M, Mezi S, Marchetti P (2021) The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study. J Pers Med 11(7):651. https:\/\/doi.org\/10.3390\/jpm11070651","journal-title":"J Pers Med"},{"issue":"31","key":"3384_CR79","doi-asserted-by":"publisher","first-page":"11695","DOI":"10.1073\/pnas.0601347103","volume":"103","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P, Kurahara C, Lott F, Sun N, Welcher AA, Dong C (2006) Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A 103(31):11695\u201311700. https:\/\/doi.org\/10.1073\/pnas.0601347103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3384_CR80","doi-asserted-by":"publisher","first-page":"974087","DOI":"10.3389\/fimmu.2022.974087","volume":"13","author":"A Botticelli","year":"2022","unstructured":"Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P (2022) The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. Front Immunol 13:974087. https:\/\/doi.org\/10.3389\/fimmu.2022.974087","journal-title":"Front Immunol"},{"issue":"5","key":"3384_CR81","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1084\/jem.20130790","volume":"211","author":"Y Xiao","year":"2014","unstructured":"Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH, DeKruyff RH, Freeman GJ (2014) RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 211(5):943\u2013959. https:\/\/doi.org\/10.1084\/jem.20130790","journal-title":"J Exp Med"},{"issue":"2","key":"3384_CR82","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama N, Tanaka R (2022) Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int 71(2):169\u2013178. https:\/\/doi.org\/10.1016\/j.alit.2022.01.001","journal-title":"Allergol Int"},{"issue":"2","key":"3384_CR83","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/rheumatology\/keab360","volume":"61","author":"X Zhang","year":"2022","unstructured":"Zhang X, Lu H, Peng L, Zhou J, Wang M, Li J, Liu Z, Zhang W, Zhao Y, Zeng X, Lu L (2022) The role of PD-1\/PD-Ls in the pathogenesis of IgG4-related disease. Rheumatology 61(2):815\u2013825. https:\/\/doi.org\/10.1093\/rheumatology\/keab360","journal-title":"Rheumatology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03384-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:45:31Z","timestamp":1729017931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3384"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03384-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"16 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PAOLO MARCHETTI (PM) has\/had a consultant\/advisory role for BMS, Roche-Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided a written informed consent, and the protocol approval of Local Ethics Committee was obtained [CE 5618]. All the procedures performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}